Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type) m+ u' F2 |! q# ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 6 O/ B/ S8 m* N! K0 ?' u S
+ Author Affiliations/ I3 t( Z; ?6 B) _
9 j# r) y3 ?3 M; a9 a1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 9 {1 ~3 Q+ [7 }- S0 f& {! A
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( ?. T4 x1 f/ Y1 T3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan : b( i& K2 R+ v4 }* [# a
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
, k. t" o; g0 o5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan : A3 W# Y H: i7 |; F* T
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
) ^ h; s C- n8 b7 k0 e1 t7Kinki University School of Medicine, Osaka 589-8511, Japan
6 Q5 y3 r0 e% Q8Izumi Municipal Hospital, Osaka 594-0071, Japan
+ A& g, y) S1 E3 n1 H9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
5 k' m( s/ @& c) K% p' o8 E& G: FCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
- `* E2 t: m7 TAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
9 [% F4 V6 y- w3 T( W3 w
7 V1 y( K3 y& c* q2 H |